Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.
While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.
5 Questions with Dan Gincel, PhD, Executive Director, MD Stem Cell Research Fund at TEDCO “5 Questions With……” is a weekly BioBuzz series where we reach out to interesting people [….]
Baltimore’s Gemstone Biotherapeutics Poised to Transform Wound Care Market October 16, 2018 In the U.S. alone, there are over 100 million chronic wound visits every year. By 2020, the general [….]
Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients “We are here to bring the Community together to change the world!” opened [….]
